about
Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cellsMetformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer CellsSmall Molecule APY606 Displays Extensive Antitumor Activity in Pancreatic Cancer via Impairing Ras-MAPK SignalingTargeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals.Circulating miRNAs in cancer: from detection to therapy.GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma.Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo.Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasisMicelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.In vivo delivery of miRNAs for cancer therapy: challenges and strategies.Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study.Identification of stable housekeeping genes in response to ionizing radiation in cancer research.Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis.A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerGPR68, a proton-sensing GPCR, mediates interaction of cancer associated fibroblasts and cancer cells.Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.Precision medicine meets the DNA damage response in pancreatic cancer.
P2860
Q28468351-F11DF816-A169-4684-96F2-E3B786D8364AQ28547140-581F5C71-DE7D-4697-8D5F-4CB55AC276ACQ28552433-09140E8F-CF15-40CD-BD24-49A1812020F0Q33361738-630BB1D7-3CC4-400A-BE6D-4DE8715D57BBQ34045380-4E9D228A-B6A6-498C-86A3-193AD9EE365DQ34227791-99D99B41-D1D6-4BD8-86FB-14A86EC9D355Q34489433-6265BD71-6409-43AF-8FC1-6EEC188A3881Q34728385-30898DFC-C0D8-4A12-8F6D-72EE4520D13EQ35552067-649FB77D-5476-4FA1-A9BD-EB1A822457E7Q36140625-E0C98C8F-2EAF-4C9D-B14B-1436B37636D5Q36516568-31961D5E-AC59-4FBD-88BA-428124C5FD04Q36549751-611BD6E3-499E-4B90-AD8F-C1988325D9F9Q36984038-B8BF86FC-3CC7-4648-821D-7199C3DFFD2BQ37085804-89A95047-70B2-4CFD-837C-A04BE0608135Q37228217-B59B6F13-25B1-4694-A86F-24394C6B99EDQ37265792-29C99455-AFEA-4768-809A-2FD93CCBBE76Q37687744-6D382505-8024-4115-A5AD-6AEFDA621454Q37688099-EE56C3B5-2980-4A6C-B008-DBC7B3E4F996Q37732028-876FFE5B-DFB7-466E-8888-BF1A47364D29Q38713554-E7B856E8-5630-4634-B823-E9068C5196AEQ38718324-89D1D991-5985-4BF4-AB13-2AEED5F61F6BQ38731776-34D73D83-68CB-418E-97AE-FB74A5003B86Q38736389-284A276D-7E06-4373-AB58-571C51C8BB13Q38902585-4D871D89-6976-4AF8-BCA9-08A065397B96Q39028343-3DB4C518-5304-4C47-AB62-9A3D41AC20D3Q39515411-CEB898E2-3E40-4BD9-BC7F-C99E01162711Q46218367-1599436F-2C14-4B70-A642-13F4BFC34595Q47123105-50645444-A78B-4C7A-A2CB-C155252B4B98Q47903216-73372FCD-BFC3-43A8-81E5-436B61F75F1CQ55343373-149A8999-4252-4D2F-A1CB-F46CE869610B
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Smarter drugs emerging in pancreatic cancer therapy.
@ast
Smarter drugs emerging in pancreatic cancer therapy.
@en
Smarter drugs emerging in pancreatic cancer therapy.
@nl
type
label
Smarter drugs emerging in pancreatic cancer therapy.
@ast
Smarter drugs emerging in pancreatic cancer therapy.
@en
Smarter drugs emerging in pancreatic cancer therapy.
@nl
prefLabel
Smarter drugs emerging in pancreatic cancer therapy.
@ast
Smarter drugs emerging in pancreatic cancer therapy.
@en
Smarter drugs emerging in pancreatic cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Smarter drugs emerging in pancreatic cancer therapy.
@en
P2093
L Perkhofer
T Seufferlein
P2860
P304
P356
10.1093/ANNONC/MDU013
P577
2014-03-14T00:00:00Z